Our findings mechanistically link constitutively active STAT3 to HR impairment in EBV-transformed cells and support the idea that EBV-lymphomas including LPD, BL, and certain DLBCL (Diffuse Large B-Cell Lymphomas) may be susceptible to synthetic lethal approaches including PARP inhibition. This evidence concerns the gene STAT3 and Burkitt lymphoma.